EPCAM and neoplasm: The in vivo imaging results of the two animal groups treated with either non-targeted or targeted formulations suggest that the high tumor targeting and no remarkable side effects of Apt-PEG-Au-NPs@5-FU nanocarriers during the treatment period might be due to specific aptamer and EpCAM interactions leading to successful internalization of these nanocarriers.